The stomach cancer proteome
Stomach cancer, also termed gastric cancer or gastric carcinoma, is the fifth most common cancer in the world and the fourth leading cause of cancer-related mortality. The global 5-year survival rate is 20%. Stomach cancer occurs most often in men over the age of 40 and is common in Japan, Chile, and Iceland.The main risk factor for developing this type of cancer is Helicobacter pylori infection. Other risk factors include a history of adenomatous gastric polyps, chronic atrophic gastritis or pernicious anemia as well as smoking and consumption of salted, cured or smoked foods. A genetic component is present in approximately 10% of all cases.
Stomach cancer originates from the mucosa of the stomach and consist of adenocarcinoma of varying architecture, grade of differentiation and mucin content. Clinical classification into different stages is necessary for determining the most suitable therapy. Tumors restricted to the stomach and with no metastasis are treated with a combination of surgery, chemotherapy, radiotherapy and/or target therapy. Metastasized tumors are not curable and associated with more dismal prognosis.
Here, we explore the stomach cancer proteome using TCGA transcriptomics data and antibody based protein data.
297 genes are suggested as prognostic based
on transcriptomics data from 354 patients; 169 genes
associated with unfavourable prognosis and 128 genes associated with favourable prognosis.
TCGA data analysis
In this metadata study we used data from TCGA where transcriptomics data was available from 354 patients in total, 125 females and 229 males. Most patients (208 patients) were still alive at the time of data collection. The stage distribution was stage i) 48 patients, stage ii) 110 patients, stage iii) 146 patients, stage iv) 35 patients and 15 patients with missing stage information.
Unfavourable prognostic genes in stomach cancer
For unfavourable genes, higher relative expression levels at diagnosis gives significantly lower overall survival for the patients.
There are 169 genes
associated with unfavourable prognosis in stomach cancer. In Table 1, the top 20 most significant genes related to unfavourable prognosis are listed.
AK4 is a gene associated with unfavourable prognosis in stomach cancer. The best separation is achieved by an expression cutoff at 6.1 fpkm which divides the patients into two groups with 25% 5-year survival for patients with high expression versus 41% for patients with low expression, p-value: 4.87e-4. Immunohistochemical staining using an antibody targeting AK4 (HPA049461) shows differential expression pattern in stomach cancer samples.
Table 1. The 20 genes with highest significance associated with unfavourable prognosis in stomach cancer.
Favourable prognostic genes in stomach cancer
For favourable genes, higher relative expression levels at diagnosis gives significantly higher overall survival for the patients.
There are 128 genes associated with favourable prognosis in stomach cancer. In Table 2, the top 20 most significant genes related to favourable prognosis are listed.
CLDN7 is a gene associated with favourable prognosis in stomach cancer. The best separation is achieved by an expression cutoff at 48.5 fpkm which divides the patients into two groups with 42% 5-year survival for patients with high expression versus 19% for patients with low expression, p-value: 4.09e-4. Immunohistochemical staining using an antibody targeting CLDN7 (HPA014703) shows differential expression pattern in stomach cancer samples.
ANAPC2 is another gene associated with favourable prognosis in stomach cancer. The best separation is achieved by an expression cutoff at 5.4 fpkm which divides the patients into two groups with 42% 5-year survival for patients with high expression versus 11% for patients with low expression, p-value: 2.87e-4. Immunohistochemical staining using an antibody targeting ANAPC2 (CAB018692) shows differential expression pattern in stomach cancer samples.
Table 2. The 20 genes with highest significance associated with favourable prognosis in stomach cancer.
The stomach cancer transcriptome
The transcriptome analysis shows that 73% (n=14207) of all human genes (n=19571)
are expressed in stomach cancer. All genes were classified according to the stomach cancer-specific expression into one of five different categories, based
on the ratio between mRNA levels in stomach cancer compared to the mRNA levels in the other 16 analyzed cancer tissues. 151 genes show some level of elevated expression
in stomach cancer compared to other cancers (Figure 1). The elevated category is further subdivided into three categories as shown in Table 3.
Figure 1. The distribution of all genes across the five categories based on transcript abundance in stomach cancer as well as in all other cancer tissues.
Table 3. Number of genes in the subdivided categories of elevated expression in stomach cancer
Number of genes
||At least five-fold higher mRNA levels in a particular cancer as compared to all other cancers
||At least five-fold higher mRNA levels in a group of 2-7 cancers
||At least five-fold higher mRNA levels in a particular cancer as compared to average levels in all cancers
||Total number of elevated genes in stomach cancer
Stomach cancer is commonly diagnosed based on biopsy obtained through gastroscopy. Gastroscopy entails the insertion of a fiber optic camera into the stomach to examine the gastric mucosa and more easily collect biopsy samples. In Stage 0, the cancer is limited to the inner lining of the stomach and this early stage is treatable by endoscopic mucosal resection, or by gastrectomy and lymphadenectomy without a need for chemotherapy or radiation. Stage I tumors penetrate to the second or third layers of the stomach (IA) or to the second layer and nearby lymph nodes (IB). Stage IA is treated by surgery and Stage IB may in addition to surgery, be treated with chemotherapy (5-fluorouracil) and radiation therapy. In Stage II, the tumor penetrates to the second layer of the stomach and involve more distant lymph nodes. Patients with stage II receive the same treatment as for Stage I tumors, sometimes with the addition of neoadjuvant chemotherapy. Stage III is characterized by penetration to the third layer and metastases in more distant lymph nodes and is treated in the same way as stage. Stage IV involved spread to adjacent tissues or metastasis to distant organs. A cure is very rarely possible at this stage and treatment to prolong life or reduce symptoms may be implemented, including laser treatment, chemotherapy, surgery, and/or stents to keep the digestive tract open.
There are four major histologic types of stomach cancers: tubular, papillary, mucinous and poorly cohesive carcinoma (including signet-ring cell carcinomas). Tubular and papillary adenocarcinomas are the most common histologic type of early stomach cancer.The tubular type is composed of irregular glands that form fused or branched tubules and papillary carcinoma are characterized by epithelial projections. Mucinous adenocarcinoma accounts for 10% of gastric cancers and typically shows extracellular pools of mucin. Signet-ring cell carcinomas consist of mucin containing cells. In immunohistochemical assays 50% of stomach cancers express cytokeratin 7 and 75% are positive for cytokeratin 20. Stomach cancer is discriminated from metastatic colorectal cancer by showing SATB2 negative immunohistochemical results.
Relevant links and publications
Uhlen M et al, 2017. A pathology atlas of the human cancer transcriptome. Science.
PubMed: 28818916 DOI: 10.1126/science.aan2507
Cancer Genome Atlas Research Network et al, 2013. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet.
PubMed: 24071849 DOI: 10.1038/ng.2764
UhlÚn M et al, 2015. Tissue-based map of the human proteome. Science
PubMed: 25613900 DOI: 10.1126/science.1260419
Gremel G et al, 2014. The human gastrointestinal tract-specific transcriptome and proteome as defined by RNA sequencing and antibody-based profiling. J Gastroenterol.
PubMed: 24789573 DOI: 10.1007/s00535-014-0958-7
Hu B et al, 2012. Gastric cancer: Classification, histology and application of molecular pathology. J Gastrointest Oncol.
PubMed: 22943016 DOI: 10.3978/j.issn.2078-6891.2012.021
Karimi P et al, 2014. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev.
PubMed: 24618998 DOI: 10.1158/1055-9965.EPI-13-1057
Histology dictionary - Stomach cancer